First OSD Facility Commences Operations
(AF)

Hormonal Production Facility commenced
(AF)

New Sterile FDF Facility commenced
(IM)

New OSD Facility commenced
(AG)

WHO Geneva Pre Qualification / INVIMA approval
(AF)

- UKMHRA/ ANVISA /PICS approval
(IM)

- EU-GMP/ approval
(AG)

- New R&D Centre at Bengaluru commenced operations

TGA Australia, Health Canada
(AG)

USFDA approved with Zero 483
(IM)

-ANDA Approvals~02
- ANDA Filings~05

USFDA GMP inspection renewal
(IM)

- EU GMP renewal*
(AF/AG/IM)

- ANDA Approvals~10
- ANDA Filings~15

- Sterile Capacity expansion with investment of USD 100 million (Targeted Completion: May 2024)
- General Liquid/Lyophilized ~60 million
- Oncology Liquid/Lyophilized ~60 million
- Ophthalmics ~30 million
- PFS/Cartridge ~24 million (IM)
- ANDA Approvals ~15 (IM)
- ANDA Fillings ~16 (IM/AG)
- USFDA Approval (AG)

- USD 200 Million Revenue
- ANDA Fillings Target ~50+
(AG/AF/IM/IM)